Precision medicine market seen reaching $456.81 billion by 2035

The global precision medicine market is projected to grow from $134.10 billion in 2026 to $456.81 billion by 2035, driven by falling genome sequencing costs, faster companion-diagnostic reviews and AI tools that speed treatment selection. Government genomics programs in the U.S., Europe, India and Asia are also building the data infrastructure that is accelerating adoption.

Why it matters: - Precision medicine is moving from a niche clinical approach to a mainstream market with broad impact on cancer care, rare disease treatment, drug development and prescribing safety. - Market Research Future projects the global market will rise from $134.10 billion in 2026 to $456.81 billion by 2035, implying a 14.72% CAGR. - The report says early-adopter health systems have cut adverse drug reaction rates by an estimated 25% when pharmacogenomics matching is built into prescribing workflows.

What happened: - Market Research Future published a forecast on June 8, 2026, saying the precision medicine market was valued at $118.23 billion in 2025. - The report pegs 2035 market size at $456.81 billion and describes AI diagnostics, genomics programs and companion diagnostics as the main growth engines. - The forecast also includes a free sample report, a customization request page and a full research report link: Request a free sample, Ask for customization and Read the detailed insights.

The details: - Next-generation sequencing remains the dominant technology segment, with about 38% share in 2025. - Sequencing costs have fallen below $200 per genome, according to the report, and NCCN and ESMO guidelines now mandate NGS for 15+ tumor types. - AI and machine learning is the fastest-growing technology segment, projected at a 19.3% CAGR from 2026 to 2035. - The FDA approved 171 AI/ML-enabled medical devices in 2024, up 35% from a year earlier. - Bioinformatics and big data analytics generated $28.4 billion in revenue in 2025. - Oncology is the largest application segment, with about 43.5% share in 2025. - Rare and genetic disorders are the fastest-growing application area, at 17.1% CAGR. - Pharmaceutical and biotechnology companies are the largest end-user segment, holding about 48% share in 2025. - Hospitals and clinical laboratories generated $26.8 billion in 2025. - Home-care settings are the fastest-growing end-user category, at 17.0% CAGR.

Between the lines: - The report frames precision medicine as a data-scale business, not just a clinical testing category. - Government genomics programs are creating the population-level datasets needed for biomarker discovery, pharmacogenomics matching and targeted therapy development. - The U.S. All of Us Research Program has enrolled more than 800,000 participants and plans to sequence one million genomes with a $3.1 billion commitment. - The European Health Data Space, adopted in June 2024, is designed to allow secondary use of health data across all 27 EU member states by 2027. - India’s Genome India Initiative has announced a $280 million expansion to sequence 100,000 genomes by 2027. - Companion-diagnostic regulation is also getting faster: the FDA’s 2023 guideline revision cut co-development review time from about 12 months to roughly 7 months, and the EMA introduced a similar structure in early 2024. - Roche’s May 2025 FDA approval for the VENTANA MET (SP44) RxDx Assay shows how regulatory changes are speeding targeted therapy commercialization. - The report estimates the top five players control 28% to 34% of global revenue, suggesting a competitive market with meaningful barriers in data aggregation and regulatory expertise.

What’s next: - The report expects AI-driven clinical decision support to influence more than 60% of oncology treatment selections in leading countries by 2030. - Decentralized clinical trials using wearables, remote monitoring and at-home sample collection are projected to account for 40% of Phase II/III precision oncology trials by 2028. - WHO’s Genomics Implementation Strategy calls for 50 low- and middle-income countries to establish pharmacogenomics drug-matching capabilities by 2030. - The report argues the next phase of growth will favor data-platform companies that can combine genomic, clinical and payer data into recurring-revenue businesses.

The bottom line: - Precision medicine is entering a scaling phase powered by cheaper sequencing, faster regulation and AI tools that shorten the path from data to treatment choice.